볼트 바이오테라퓨틱스(BOLT)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.35 (+0.15%), 시가총액 $0.01B, 52주 최저~최고 $0.30 ~ $7.09.
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1
볼트 바이오테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
볼트 바이오테라퓨틱스의 현재 주가는 $3.35 (+0.15%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
볼트 바이오테라퓨틱스의 시가총액은 약 $0.01B입니다.
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation